NUF2 Is a Potential Immunological and Prognostic Marker for Non-Small-Cell Lung Cancer

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2022 May 23

PMID 35600043

Authors

Xia Li

Lianlian Zhang

Zhongquan Yi

Jing Zhou

Wenchun Song

Panwen Zhao

Jixiang Wu

Jianxiang Song

Qinggan Ni

Affiliations

Soon will be listed here.

Abstract

Background: Globally, non-small-cell lung cancer (NSCLC) is one of the most prevalent tumors. Various studies have investigated its etiology, but the molecular mechanism of NSCLC has not been elucidated.

Methods: The GSE19804, GSE118370, GSE19188, GSE27262, and GSE33532 microarray datasets were obtained from the Gene Expression Omnibus (GEO) database for the identification of genes involved in NSCLC development as well as progression. Then, the identified differentially expressed genes (DEGs) were subjected to functional enrichment analyses. The protein-protein interaction (PPI) network was built after which module analysis was conducted via the Search Tool for Retrieval of Interacting Genes/Proteins (STRING) and Cytoscape. There were 562 DEGs: 98 downregulated genes and 464 upregulated. These DEGs were established to be enriched in p53 signaling pathway, transendothelial leukocyte migration, cell adhesion molecules, contractions of vascular smooth muscles, coagulation and complement cascades, and axon guidance. Assessment of tumor immunity was performed to determine the roles of hub genes.

Results: There were 562 dysregulated genes, while 12 genes were hub genes. NUF2 was established to be a candidate immunotherapeutic target with potential clinical implications. The 12 hub genes were highly enriched in the p53 signaling pathway, the cell cycle, progesterone-associated oocyte maturation, cellular senescence, and oocyte meiosis. Survival analysis showed that NUF2 is associated with NSCLC occurrence, invasion, and recurrence.

Conclusion: The NUF2 gene discovered in this study helps us clarify the pathomechanisms of NSCLC occurrence as well as progression and provides a potential diagnostic and therapeutic target for NSCLC.

Citing Articles

Berberine restrains non-small cell lung cancer cell growth, invasion and glycolysis via inactivating the SPC25/NUF2 pathway.

Lv M, Chen X, Yang Q, Huang C, Lv Y, Zhang T Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39755832 DOI: 10.1007/s00210-024-03729-w.

NUF2 Expression in Cancer Tissues and Lymph Nodes Suggests Post-Surgery Recurrence of Non-Small Cell Lung Cancer.

Shirakami C, Ikeda K, Hinokuma H, Nishi W, Shinchi Y, Matsubara E Diagnostics (Basel). 2024; 14(5).

PMID: 38472943 PMC: 10930777. DOI: 10.3390/diagnostics14050471.

NUF2 Promotes Breast Cancer Development as a New Tumor Stem Cell Indicator.

Deng Y, Li J, Zhang Y, Hu H, Wan F, Min H Int J Mol Sci. 2023; 24(4).

PMID: 36835637 PMC: 9965662. DOI: 10.3390/ijms24044226.

Evaluating the Expression and Prognostic Value of Genes Encoding Microtubule-Associated Proteins in Lung Cancer.

Singharajkomron N, Yodsurang V, Seephan S, Kungsukool S, Petchjorm S, Maneeganjanasing N Int J Mol Sci. 2022; 23(23).

PMID: 36499051 PMC: 9738182. DOI: 10.3390/ijms232314724.

References

Jonna S, Subramaniam D . Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update. Discov Med. 2019; 27(148):167-170. View

Edgar R, Domrachev M, Lash A . Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2001; 30(1):207-10. PMC: 99122. DOI: 10.1093/nar/30.1.207. View

Gennen K, Kasmann L, Taugner J, Eze C, Karin M, Roengvoraphoj O . Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiat Oncol. 2020; 15(1):5. PMC: 6941268. DOI: 10.1186/s13014-019-1453-3. View

Saleh R, Elkord E . Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. Semin Cancer Biol. 2019; 65:13-27. DOI: 10.1016/j.semcancer.2019.07.017. View

Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A . STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2012; 41(Database issue):D808-15. PMC: 3531103. DOI: 10.1093/nar/gks1094. View

Herbst R, Morgensztern D, Boshoff C . The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689):446-454. DOI: 10.1038/nature25183. View

Hou J, Aerts J, den Hamer B, van IJcken W, den Bakker M, Riegman P . Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One. 2010; 5(4):e10312. PMC: 2858668. DOI: 10.1371/journal.pone.0010312. View

Mami-Chouaib F, Blanc C, Corgnac S, Hans S, Malenica I, Granier C . Resident memory T cells, critical components in tumor immunology. J Immunother Cancer. 2018; 6(1):87. PMC: 6122734. DOI: 10.1186/s40425-018-0399-6. View

Sugimasa H, Taniue K, Kurimoto A, Takeda Y, Kawasaki Y, Akiyama T . Heterogeneous nuclear ribonucleoprotein K upregulates the kinetochore complex component NUF2 and promotes the tumorigenicity of colon cancer cells. Biochem Biophys Res Commun. 2015; 459(1):29-35. DOI: 10.1016/j.bbrc.2015.02.043. View

10.

Bandettini W, Kellman P, Mancini C, Booker O, Vasu S, Leung S . MultiContrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn Reson. 2012; 14:83. PMC: 3552709. DOI: 10.1186/1532-429X-14-83. View

11.

Schabath M, Cote M . Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019; 28(10):1563-1579. PMC: 6777859. DOI: 10.1158/1055-9965.EPI-19-0221. View

12.

Sandfeld-Paulsen B, Jakobsen K, Baek R, Folkersen B, Rasmussen T, Meldgaard P . Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer. J Thorac Oncol. 2016; 11(10):1701-10. DOI: 10.1016/j.jtho.2016.05.034. View

13.

Kishikawa T, Kasai T, Okada M, Nakachi I, Soda S, Arai R . Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Thorac Cancer. 2020; 11(4):935-942. PMC: 7113046. DOI: 10.1111/1759-7714.13378. View

14.

Wu P, Gao W, Su M, Nice E, Zhang W, Lin J . Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. Front Cell Dev Biol. 2021; 9:641469. PMC: 7957022. DOI: 10.3389/fcell.2021.641469. View

15.

Smoot M, Ono K, Ruscheinski J, Wang P, Ideker T . Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2010; 27(3):431-2. PMC: 3031041. DOI: 10.1093/bioinformatics/btq675. View

16.

Shukla S, Evans J, Malik R, Feng F, Dhanasekaran S, Cao X . Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. J Natl Cancer Inst. 2016; 109(1). PMC: 5051943. DOI: 10.1093/jnci/djw200. View

17.

Kanehisa M . The KEGG database. Novartis Found Symp. 2003; 247:91-101; discussion 101-3, 119-28, 244-52. View

18.

Hu P, Chen X, Sun J, Bie P, Zhang L . siRNA-mediated knockdown against NUF2 suppresses pancreatic cancer proliferation in vitro and in vivo. Biosci Rep. 2014; 35(1). PMC: 4293903. DOI: 10.1042/BSR20140124. View

19.

Wei T, Juan C, Hisa J, Su L, Lee Y, Chou H . Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade. Cancer Sci. 2012; 103(9):1640-50. PMC: 7659304. DOI: 10.1111/j.1349-7006.2012.02367.x. View

20.

Naylor E, Desani J, Chung P . Targeted Therapy and Immunotherapy for Lung Cancer. Surg Oncol Clin N Am. 2016; 25(3):601-9. DOI: 10.1016/j.soc.2016.02.011. View